Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fish and Richardson
US Army
McKinsey
Accenture
Cipla
Johnson and Johnson
Chinese Patent Office
Dow

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,655,637

« Back to Dashboard

Summary for Patent: 7,655,637
Title:N-pyrazole A.sub.2A receptor agonists
Abstract:2-adenosine N-pyrazole compounds having the following formula: ##STR00001## wherein R.sup.1.dbd.CH.sub.2OH; R.sup.2 is hydrogen; R.sup.3 is selected from the group consisting of CO.sub.2R.sup.20; --CONR.sup.7R.sup.8 ,and aryl wherein the aryl substituent is optionally substituted with one substituent selected from the group consisting of halo, C .sub.1-3alkyl and OR.sup.20;R.sup.4 is hydrogen; R.sup.7 is selected from hydrogen, and C.sub.1-3alkyl; R.sup.8 is hydrogen; and R.sup.20 is selected from hydrogen and methyl as well as methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.
Inventor(s): Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Fremont, CA), Palle; Venkata (Pune, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee: Gilead Palo Alto, Inc. (Foster City, CA)
Application Number:11/588,834
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 7,655,637

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,655,637

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,045,519 N-pyrazole A.sub.2A receptor agonists ➤ Try a Free Trial
7,144,872 N-pyrazole A.sub.2A receptor agonists ➤ Try a Free Trial
7,183,264 N-pyrazole A2A receptor agonists ➤ Try a Free Trial
6,403,567 N-pyrazole A2A adenosine receptor agonists ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,655,637

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 024441 ➤ Try a Free Trial
Austria 256141 ➤ Try a Free Trial
Australia 7132400 ➤ Try a Free Trial
Australia 760806 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Dow
Healthtrust
Cerilliant
Accenture
McKesson
AstraZeneca
Farmers Insurance
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.